Innovations for Next-Generation Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. Thi
- PDF / 10,674,345 Bytes
- 358 Pages / 439.42 x 683.15 pts Page_size
- 31 Downloads / 289 Views
Marc Damelin Editor
Innovations for Next-Generation Antibody-Drug Conjugates
Cancer Drug Discovery and Development Series Editor Beverly A. Teicher Bethesda, Maryland, USA
The Cancer Drug Discovery and Development series (Beverly A Teicher, series editor) is the definitive book series in cancer research and oncology, providing comprehensive coverage of specific topics and the field. Volumes cover the process of drug discovery, preclinical models in cancer research, specific drug target groups and experimental and approved therapeutic agents. The volumes are current and timely, anticipating areas where experimental agents are reaching FDA approval. Each volume is edited by an expert in the field covered and chapters are authored by renowned scientists and physicians in their fields of interest.
More information about this series at http://www.springer.com/series/7625
Marc Damelin Editor
Innovations for Next-Generation Antibody-Drug Conjugates
Editor Marc Damelin Mersana Therapeutics, Inc. Cambridge, MA, USA
ISSN 2196-9906 ISSN 2196-9914 (electronic) Cancer Drug Discovery and Development ISBN 978-3-319-78153-2 ISBN 978-3-319-78154-9 (eBook) https://doi.org/10.1007/978-3-319-78154-9 Library of Congress Control Number: 2018941851 © Springer International Publishing AG, part of Springer Nature 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Humana Press imprint is published by the registered company Springer International Publishing AG part of Springer Nature. The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Chemotherapy is good but not good enough: it is standard-of-care treatment for many tumor types, yet its efficacy is matched by and limited by toxicity. The concept of the antibody-drug conjugate (ADC) – to deliver chemotherapy preferentially to tumor tissue by conjug
Data Loading...
